WARREN,
N.J., Jan. 13, 2025 /PRNewswire/ -- PTC
Therapeutics, Inc. (NASDAQ: PTCT) today announced that on
Jan. 3, 2025, the company approved
1,200 restricted stock units ("RSUs"), each representing the right
to receive one share of its common stock upon vesting, to two new
employees. The awards were made pursuant to the Nasdaq inducement
grant exception as a component of the new hires' employment
compensation.
The inducement grants were approved by PTC's Compensation
Committee on Jan. 3, 2025, and are being made as an inducement
material to each employee's acceptance of employment with the
company in accordance with Nasdaq Listing Rule 5635(c)(4).
The RSUs each will vest over four years with 25% of the original
number of shares vesting on each annual anniversary of the
applicable employee's new hire date until fully vested, subject to
the employee's continued service with the company through the
applicable vesting dates.
ABOUT PTC THERAPEUTICS, INC.
PTC is a global
biopharmaceutical company that discovers, develops and
commercializes clinically differentiated medicines that provide
benefits to children and adults living with rare disorders. PTC's
ability to innovate to identify new therapies and to globally
commercialize products is the foundation that drives investment in
a robust and diversified pipeline of transformative medicines. To
learn more about PTC, please visit us
at www.ptcbio.com and follow us on Facebook, Instagram,
LinkedIn and X.
For more information please contact:
Investors:
Ellen
Cavaleri
+1 (615) 618-8228
ecavaleri@ptcbio.com
Media:
Jeanine
Clemente
+1 (908) 912-9406
jclemente@ptcbio.com
View original
content:https://www.prnewswire.com/news-releases/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-302349732.html
SOURCE PTC Therapeutics, Inc.